VERU: Rata-rata rega prakiraan Veru Pharma

Simbol lan logo merek Veru Inc (VERU)

Veru Inc. (VERU) is a biopharmaceutical player whose model relies on high margins within narrow niches of women's health and oncology, with growth potential following FDA approval tied to low-cost mass production coupled with monopoly pricing power. This price chart captures the asset's dynamics, where the metric stands at 25.64. The business is currently pivoting its development toward muscle preservation during obesity treatment, scaling its clinical trials.

VERU: Target konsensus Veru Inc. 04.07.2022 - 22.10.2026

Rincian analitis perusahaan Veru Pharma (VERU)

Analisis fundamental perusahaan:verupharma.com (VERU)
Produk asli Veru Pharma

Amidst fierce competition between Veru Inc. (VERU) and global pharmaceutical behemoths in the oncology sector, any correction in drug approval expectations instantaneously impacts market capitalization. The consensus target price history aggregates average estimates from leading banks, reflecting a fundamental revaluation of asset costs and debt service risks, which allows investors to identify reversals in the company's cash balance.

Perusahaan pesaing

Bagan rega target ONC (beigene.com)|Prakiraan konsensus analis HALO (Halozyme)|Revolution Medicines Inc (RVMD) - Rata-rata rega prakiraan|AAPG - Bagan rega target|Konsensus nilai wajar CGON (CG Oncology Therapeutics)|URGN (UroGen Pharma Ltd.) - Target konsensus|bicara.com (BCAX) - Prakiraan konsensus analis|PSNL (Personalis) - Prakiraan konsensus analis|Target konsensus Erasca Inc (ERAS)|Prakiraan konsensus analis DCTH|Prakiraan konsensus analis Y-mAbs Corp (YMAB)|Bagan rega target Aura Biosciences, Inc. AURA|CADL: Prakiraan gabungan firma investasi|Accuray - Prakiraan konsensus analis|SELLAS Life Sciences (SLS) - Target konsensus|ACTU: Prakiraan konsensus analis|Rata-rata rega prakiraan Citius Oncology Inc (CTOR)|Bagan rega target TuHURA Biosciences Inc.|TARA: Konsensus nilai wajar|Target konsensus FATE (Fate Therapeutics)|WHWK (aadibio.com) - Konsensus nilai wajar|Prakiraan konsensus analis TCRX (TScan Therapeutics, Inc.)|CSBR - Target konsensus|XBIT: Target konsensus|CVM - Prakiraan konsensus analis|OS Therapies (OSTX) - Bagan rega target|Radiopharm Theranostics Ltd - Konsensus nilai wajar|ARTV (Artiva Biotherapeutics Inc.) - Prakiraan konsensus analis|Rata-rata rega prakiraan Adlai Nortye Limited ANL|Target konsensus TPST (Tempest Therapeutics)|Bagan rega target XLO (xiliotx.com)|Prakiraan konsensus analis RENB (Renovaro)|Mural Oncology PLC (MURA) - Rata-rata rega prakiraan|KAPA - Bagan rega target|Konsensus nilai wajar OKUR (OnKure Therapeutics Inc)|GDTC (w2.cytomed.sg) - Target konsensus|Curis (CRIS) - Prakiraan konsensus analis|Target konsensus APLM|THAR: Konsensus nilai wajar|Prakiraan konsensus analis ADVB|Target median analis Genprex Inc|Bagan rega target Calidi Biotherapeutics, Inc. CLDI|SBFM: Prakiraan gabungan firma investasi|Xenetic Bio - Prakiraan konsensus analis|Salarius Pharmaceuticals Inc (SLRX) - Target konsensus|PPBT (Purple Biotech Corp) - Target konsensus|AONC - Target median analis|Target konsensus BGNE|Bagan rega target CKPT|Prakiraan konsensus analis ELEV|ICAD - Rata-rata rega prakiraan|Bagan rega target Ikena Oncology IKNA|Konsensus nilai wajar NTBL|VIRX: Target konsensus|MOR - Prakiraan konsensus analis|NAYA: Prakiraan konsensus analis|Target konsensus Ascentage Pharma Group International